Desidustat vs Vadadustat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline

Desidustat · Oxemia

Marketed by Zydus Lifesciences and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT04012957 · Phase 3 · completed

The study was randomized and used an active darbepoetin comparator, but it was open-label and its primary outcome was change in hemoglobin, a surrogate laboratory measure rather than a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Hemoglobin level (24 weeks): Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382) (met)

Result source: NCT04215120

Vadadustat · Vafseo

Marketed by Akebia Therapeutics and partners

Approved in Chronic Kidney Diseasesmall molecule
Partial signal

NCT02648347 · Phase 3 · completed

Participants were randomized to vadadustat or active treatment with darbepoetin alfa, but the trial was open-label; 879 received vadadustat and 872 received darbepoetin alfa. The hemoglobin primary endpoint met the prespecified non-inferiority criterion, while the primary cardiovascular safety comparison did not, making the findings mixed rather than clearly positive.

Next expected readout: April 2027 · NCT07565701 (registry estimate)

Reported efficacy

Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36); Median Time to First Major Adverse Cardiovascular Event (MACE) (Up to Week 208): Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 0.41 Grams per deciliter (g/dL) (Standard Error 0.036) vs Darbepoetin Alfa 0.42 Grams per deciliter (g/dL) (Standard Error 0.037) (mixed)

Result source: NCT02680574

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDesidustatVadadustat
Kidney composite outcome—Not posted · NCT04012957—Not posted · NCT02892149
UACR, % change—Not posted · NCT04012957—Not posted · NCT02892149
eGFR slope—Not posted · NCT04012957—Not posted · NCT02892149
Haemoglobin, change1.9 vs 1.8avs darbepoetinNCT04012957
1 other result
1.4 vs 1.4vs Darbepoetin Alfan 879NCT02648347
34 other results
  • 0.4 vs 0.4 wk 52 · n 862 · Phase 3 · secondary NCT02680574
  • 1.5 vs 1.5 n 879 · Phase 3 · secondary NCT02648347
  • 0.2 vs 0.4 n 1777 · Phase 3 · secondary NCT02892149
  • 1.4 vs 1.5 wk 52 · n 181 · Phase 3 · secondary NCT02865850
  • 0.9 vs -0.1 wk 20 · n 135 · Phase 2 · secondary NCT01906489
  • 0.7 vs -0.2 wk 19 · n 135 · Phase 2 · secondary NCT01906489
  • 0.8 vs -0.2 wk 16 · n 135 · Phase 2 · secondary NCT01906489
  • 0.9 vs -0.2 wk 12 · n 135 · Phase 2 · secondary NCT01906489
  • 0.7 vs -0.4 wk 8 · n 135 · Phase 2 · secondary NCT01906489
  • 0.6 vs -0.4 wk 6 · n 135 · Phase 2 · secondary NCT01906489
  • 0.4 vs -0.3 wk 4 · n 135 · Phase 2 · secondary NCT01906489
  • 0.1 vs -0.2 wk 2 · n 135 · Phase 2 · secondary NCT01906489
  • 1.4 vs -0.0 630 mg · wk 6 · n 19 · Phase 2 · secondary NCT01381094
  • 1.1 vs 0.1 630 mg · wk 4 · n 19 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 630 mg · wk 2 · n 19 · Phase 2 · secondary NCT01381094
  • 0.3 vs 0.0 630 mg · wk 1 · n 19 · Phase 2 · secondary NCT01381094
  • 1.3 vs -0.0 500 mg · wk 6 · n 17 · Phase 2 · secondary NCT01381094
  • 0.8 vs 0.1 500 mg · wk 4 · n 17 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 500 mg · wk 2 · n 17 · Phase 2 · secondary NCT01381094
  • 0.3 vs 0.0 500 mg · wk 1 · n 17 · Phase 2 · secondary NCT01381094
  • 0.7 vs -0.0 370 mg · wk 6 · n 16 · Phase 2 · secondary NCT01381094
  • 0.4 vs 0.1 370 mg · wk 4 · n 16 · Phase 2 · secondary NCT01381094
  • 0 vs 0.1 370 mg · wk 2 · n 16 · Phase 2 · secondary NCT01381094
  • -0.1 vs 0.0 370 mg · wk 1 · n 16 · Phase 2 · secondary NCT01381094
  • 0.8 vs -0.0 240 mg · wk 6 · n 18 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 240 mg · wk 4 · n 18 · Phase 2 · secondary NCT01381094
  • 0.2 vs 0.1 240 mg · wk 2 · n 18 · Phase 2 · secondary NCT01381094
  • 0.1 vs 0.0 240 mg · wk 1 · n 18 · Phase 2 · secondary NCT01381094
  • -0.2 vs 0.1 300 mg · wk 20 · n 26 · Phase 2 · secondary NCT03799627
  • -0.2 vs 0.1 450 mg · wk 20 · n 24 · Phase 2 · secondary NCT03799627
  • 0.1 vs 0.1 300 mg · wk 20 · n 7 · Phase 2 · secondary NCT03799627
  • -0.5 vs 0.1 600 mg · wk 20 · n 10 · Phase 2 · secondary NCT03799627
  • -0.4 vs 0.1 450 mg · wk 20 · n 14 · Phase 2 · secondary NCT03799627
  • -0.3 vs 0.1 600 mg · wk 20 · n 3 · Phase 2 · secondary NCT03799627

Kidney composite outcome

Desidustat
—Not posted · NCT04012957
Vadadustat
—Not posted · NCT02892149

UACR, % change

Desidustat
—Not posted · NCT04012957
Vadadustat
—Not posted · NCT02892149

eGFR slope

Desidustat
—Not posted · NCT04012957
Vadadustat
—Not posted · NCT02892149

Haemoglobin, change

Desidustat
1.9 vs 1.8avs darbepoetinNCT04012957
1 other result
Vadadustat
1.4 vs 1.4vs Darbepoetin Alfan 879NCT02648347
34 other results
  • 0.4 vs 0.4 wk 52 · n 862 · Phase 3 · secondary NCT02680574
  • 1.5 vs 1.5 n 879 · Phase 3 · secondary NCT02648347
  • 0.2 vs 0.4 n 1777 · Phase 3 · secondary NCT02892149
  • 1.4 vs 1.5 wk 52 · n 181 · Phase 3 · secondary NCT02865850
  • 0.9 vs -0.1 wk 20 · n 135 · Phase 2 · secondary NCT01906489
  • 0.7 vs -0.2 wk 19 · n 135 · Phase 2 · secondary NCT01906489
  • 0.8 vs -0.2 wk 16 · n 135 · Phase 2 · secondary NCT01906489
  • 0.9 vs -0.2 wk 12 · n 135 · Phase 2 · secondary NCT01906489
  • 0.7 vs -0.4 wk 8 · n 135 · Phase 2 · secondary NCT01906489
  • 0.6 vs -0.4 wk 6 · n 135 · Phase 2 · secondary NCT01906489
  • 0.4 vs -0.3 wk 4 · n 135 · Phase 2 · secondary NCT01906489
  • 0.1 vs -0.2 wk 2 · n 135 · Phase 2 · secondary NCT01906489
  • 1.4 vs -0.0 630 mg · wk 6 · n 19 · Phase 2 · secondary NCT01381094
  • 1.1 vs 0.1 630 mg · wk 4 · n 19 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 630 mg · wk 2 · n 19 · Phase 2 · secondary NCT01381094
  • 0.3 vs 0.0 630 mg · wk 1 · n 19 · Phase 2 · secondary NCT01381094
  • 1.3 vs -0.0 500 mg · wk 6 · n 17 · Phase 2 · secondary NCT01381094
  • 0.8 vs 0.1 500 mg · wk 4 · n 17 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 500 mg · wk 2 · n 17 · Phase 2 · secondary NCT01381094
  • 0.3 vs 0.0 500 mg · wk 1 · n 17 · Phase 2 · secondary NCT01381094
  • 0.7 vs -0.0 370 mg · wk 6 · n 16 · Phase 2 · secondary NCT01381094
  • 0.4 vs 0.1 370 mg · wk 4 · n 16 · Phase 2 · secondary NCT01381094
  • 0 vs 0.1 370 mg · wk 2 · n 16 · Phase 2 · secondary NCT01381094
  • -0.1 vs 0.0 370 mg · wk 1 · n 16 · Phase 2 · secondary NCT01381094
  • 0.8 vs -0.0 240 mg · wk 6 · n 18 · Phase 2 · secondary NCT01381094
  • 0.5 vs 0.1 240 mg · wk 4 · n 18 · Phase 2 · secondary NCT01381094
  • 0.2 vs 0.1 240 mg · wk 2 · n 18 · Phase 2 · secondary NCT01381094
  • 0.1 vs 0.0 240 mg · wk 1 · n 18 · Phase 2 · secondary NCT01381094
  • -0.2 vs 0.1 300 mg · wk 20 · n 26 · Phase 2 · secondary NCT03799627
  • -0.2 vs 0.1 450 mg · wk 20 · n 24 · Phase 2 · secondary NCT03799627
  • 0.1 vs 0.1 300 mg · wk 20 · n 7 · Phase 2 · secondary NCT03799627
  • -0.5 vs 0.1 600 mg · wk 20 · n 10 · Phase 2 · secondary NCT03799627
  • -0.4 vs 0.1 450 mg · wk 20 · n 14 · Phase 2 · secondary NCT03799627
  • -0.3 vs 0.1 600 mg · wk 20 · n 3 · Phase 2 · secondary NCT03799627
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Desidustat: 1 of 5 rows · Vadadustat: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDesidustatVadadustat
Rows use multiple source trials
Hemoglobin
responder rate · % of participants
77.78% vs 68.48% darbepoetina,b,c,d
NCT04012957 · Phase 3 · sponsor-reported, not registry data
1 other source trial
59.22% vs 48.37% epoetin alfa
NCT04215120 · Phase 3 · sponsor-reported, not registry data
42.9% (n=7) vs 60.9% (n=23) Epoetin Alfa @ 20wk*300 mge,a,b,c,d
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
show 5 more doses
38.5% (n=26) vs 60.9% (n=23) Epoetin Alfa @ 20wk*300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
33.3% (n=3) vs 60.9% (n=23) Epoetin Alfa @ 20wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
20% (n=10) vs 60.9% (n=23) Epoetin Alfa @ 20wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
35.7% (n=14) vs 60.9% (n=23) Epoetin Alfa @ 20wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
45.8% (n=24) vs 60.9% (n=23) Epoetin Alfa @ 20wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
Dropout rate—
23.8%f
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 46 more results
18.3%
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
11.6%
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
19.8%
NCT02892149 · Phase 3
35.5%900 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
34.9%600 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
55.6%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
22.9%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
40%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
61.9%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
42.9%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
32.4%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
80%300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
13.3%300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
60%600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
13.3%600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
40%150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
26.7%150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
20%300 mg Once Daily (QD)
NCT02260193 · Phase 2 · registry result, not featured evidence
32.3%450 mg 3 Times Per Week (TIW)
NCT02260193 · Phase 2 · registry result, not featured evidence
27.3%450 mg QD
NCT02260193 · Phase 2 · registry result, not featured evidence
18.8%
NCT01906489 · Phase 2 · registry result, not featured evidence
5.3%630 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0%500 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
16.7%370 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
11.1%240 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0%
NCT01235936 · Phase 2 · registry result, not featured evidence
0%Cohort 1: CKD Stage 3 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
0%Cohort 2: CKD Stage 4 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
—f
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 46 more results
—
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
—
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
—
NCT02892149 · Phase 3
11.8%900 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
5.9%600 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
0%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
2.9%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
40%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
23.8%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
9.5%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
5.9%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
10%300 mg Once Daily (QD)
NCT02260193 · Phase 2 · registry result, not featured evidence
3.2%450 mg 3 Times Per Week (TIW)
NCT02260193 · Phase 2 · registry result, not featured evidence
12.1%450 mg QD
NCT02260193 · Phase 2 · registry result, not featured evidence
7.2%
NCT01906489 · Phase 2 · registry result, not featured evidence
5.3%630 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0%500 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
11.1%370 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
5.6%240 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
—
NCT01235936 · Phase 2 · registry result, not featured evidence
—Cohort 1: CKD Stage 3 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
—Cohort 2: CKD Stage 4 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
Serious AEs—
65.3%f
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 46 more results
58.5%
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
49.7%
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
55%
NCT02892149 · Phase 3
44%900 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
45%600 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
44.4%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
26.5%300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
80%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
47.6%600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
28.6%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
20%450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence
6.7%300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
6.7%600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0%600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
20%600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
6.7%150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
41.7%300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
15.4%600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
16.7%300 mg Once Daily (QD)
NCT02260193 · Phase 2 · registry result, not featured evidence
25.8%450 mg 3 Times Per Week (TIW)
NCT02260193 · Phase 2 · registry result, not featured evidence
27.3%450 mg QD
NCT02260193 · Phase 2 · registry result, not featured evidence
23.9%
NCT01906489 · Phase 2 · registry result, not featured evidence
5.3%630 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
5.9%500 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
16.7%370 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
11.1%240 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0%
NCT01235936 · Phase 2 · registry result, not featured evidence
0%Cohort 1: CKD Stage 3 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
0%Cohort 2: CKD Stage 4 Vadadustat
NCT04707573 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
f
hypertension 17.2%
diarrhoea 13%
oedema peripheral 12.5%
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 37 more results
hypertension 13.9%
diarrhoea 13.6%
urinary tract infection 10.8%
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
hypertension 15.1%
diarrhoea 10.1%
nausea 7.8%
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
diarrhoea 12.8%
hypertension 9.9%
headache 9%
NCT02892149 · Phase 3
900 mg TIW
diarrhoea 14%
covid 19 12%
hyperkalaemia 8.7%
NCT04707768 · Phase 3 · registry result, not featured evidence
600 mg TIW
covid 19 12.6%
diarrhoea 10.6%
nausea 7.9%
NCT04707768 · Phase 3 · registry result, not featured evidence
300 mg
diarrhoea 22.2%
fall 11.1%
hyperkalaemia 11.1%
NCT03799627 · Phase 2 · registry result, not featured evidence
300 mg
cough 5.9%
headache 5.9%
influenza 5.9%
NCT03799627 · Phase 2 · registry result, not featured evidence
600 mg
acarodermatitis 20%
anaemia 20%
back pain 20%
NCT03799627 · Phase 2 · registry result, not featured evidence
600 mg
diarrhoea 19%
headache 14.3%
hypertension 14.3%
NCT03799627 · Phase 2 · registry result, not featured evidence
450 mg
arteriovenous fistula thrombosis 9.5%
diarrhoea 9.5%
fall 4.8%
NCT03799627 · Phase 2 · registry result, not featured evidence
450 mg
diarrhoea 8.6%
hypertension 8.6%
nasopharyngitis 8.6%
NCT03799627 · Phase 2 · registry result, not featured evidence
300 mg
nasopharyngitis 13.3% (placebo 0%)
asthma 6.7% (placebo 0%)
cholelithiasis 6.7% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
300 mg
blood uric acid decreased 20% (placebo 0%)
nasopharyngitis 20% (placebo 0%)
abdominal pain 0% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
300 mg
nasopharyngitis 33.3% (placebo 0%)
diarrhoea 13.3% (placebo 20%)
blood parathyroid hormone increased 6.7% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
600 mg
anaemia macrocytic 6.7% (placebo 0%)
cardiac failure chronic 6.7% (placebo 0%)
dermal cyst 6.7% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
600 mg
catheter site erosion 20% (placebo 0%)
conjunctivitis 20% (placebo 0%)
diarrhoea 20% (placebo 20%)
NCT03054350 · Phase 2 · registry result, not featured evidence
600 mg
diarrhoea 13.3% (placebo 20%)
abdominal pain 6.7% (placebo 0%)
contusion 6.7% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 26.7% (placebo 0%)
contusion 13.3% (placebo 0%)
headache 13.3% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
150 mg
diarrhoea 20% (placebo 20%)
headache 20% (placebo 0%)
pneumonia 20% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
150 mg
arthralgia 6.7% (placebo 20%)
constipation 6.7% (placebo 0%)
cough 6.7% (placebo 0%)
NCT03054350 · Phase 2 · registry result, not featured evidence
300 mg
constipation 16.7% (placebo 0%)
abdominal distension 8.3% (placebo 0%)
abdominal pain 8.3% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
300 mg
hypertension 25% (placebo 0%)
nausea 16.7% (placebo 0%)
angular cheilitis 8.3% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
600 mg
benign prostatic hyperplasia 7.7% (placebo 0%)
delirium 7.7% (placebo 0%)
diarrhoea 7.7% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
600 mg
hypertension 15.4% (placebo 0%)
aspartate aminotransferase increased 7.7% (placebo 0%)
back pain 7.7% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
150 mg
contusion 16.7% (placebo 0%)
abdominal distension 8.3% (placebo 0%)
back pain 8.3% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
150 mg
influenza 8.3% (placebo 0%)
oedema due to renal disease 8.3% (placebo 0%)
orthostatic hypotension 8.3% (placebo 0%)
NCT03054337 · Phase 2 · registry result, not featured evidence
300 mg Once Daily (QD)
diarrhoea 13.3%
nausea 13.3%
arteriovenous fistula site complication 10%
NCT02260193 · Phase 2 · registry result, not featured evidence
450 mg 3 Times Per Week (TIW)
nausea 12.9%
back pain 9.7%
headache 9.7%
NCT02260193 · Phase 2 · registry result, not featured evidence
450 mg QD
abdominal pain 12.1%
diarrhoea 12.1%
dizziness 9.1%
NCT02260193 · Phase 2 · registry result, not featured evidence
diarrhoea 10.1% (placebo 4.2%)
nausea 10.1% (placebo 4.2%)
fatigue 8% (placebo 6.9%)
NCT01906489 · Phase 2 · registry result, not featured evidence
630 mg
hypertension 10.5% (placebo 15.8%)
abdominal pain 5.3% (placebo 0%)
adverse drug reaction 5.3% (placebo 0%)
NCT01381094 · Phase 2 · registry result, not featured evidence
500 mg
hyperkalaemia 17.6% (placebo 5.3%)
nausea 11.8% (placebo 10.5%)
blood bicarbonate decreased 5.9% (placebo 0%)
NCT01381094 · Phase 2 · registry result, not featured evidence
370 mg
abdominal discomfort 5.6% (placebo 0%)
abdominal pain upper 5.6% (placebo 0%)
blood uric acid increased 5.6% (placebo 0%)
NCT01381094 · Phase 2 · registry result, not featured evidence
240 mg
headache 11.1% (placebo 0%)
urinary tract infection 11.1% (placebo 0%)
constipation 5.6% (placebo 0%)
NCT01381094 · Phase 2 · registry result, not featured evidence
diarrhoea 20%
chills 10%
constipation 10%
NCT01235936 · Phase 2 · registry result, not featured evidence
nausea 20%
cold sweat 10%
headache 10%
NCT04707573 · Phase 2 · registry result, not featured evidence
back pain 8.3%
catheter site inflammation 8.3%
oropharyngeal pain 8.3%
NCT04707573 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Vadadustat

Time to First MACE 10.55 vs 10.78 Darbepoetin Alfa months
time to event · months
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 45.71 weeks as posted
show 2 more results
6.05 vs 10.76 Darbepoetin Alfa months*
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 26.21 weeks as posted
11.28 vs 11.08 Darbepoetin Alfa months*
NCT02892149 · Phase 3 · converted to months from 48.86 weeks as posted
MACE Plus HF Hosp Thromboembolic 8.69 vs 9.56 Darbepoetin Alfa months
absolute value · months
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 37.64 weeks as posted
show 3 more results
11.14 vs 11.37 Darbepoetin Alfa months*
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 48.29 weeks as posted
6.26 vs 10.85 Darbepoetin Alfa months*
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 27.14 weeks as posted
9.99 vs 10.43 Darbepoetin Alfa months*
NCT02892149 · Phase 3 · converted to months from 43.29 weeks as posted
MACE 10.58 vs 9.66 Darbepoetin Alfa months
absolute value · months
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 45.86 weeks as posted
show 4 more results
12.28 vs 13.38 Darbepoetin Alfa months*
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 53.21 weeks as posted
10.52 vs 11.61 Darbepoetin Alfa months*
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 45.57 weeks as posted
4.27 vs 12.48 Darbepoetin Alfa months*
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 18.5 weeks as posted
10.29 vs 10.05 Darbepoetin Alfa months*
NCT02892149 · Phase 3 · converted to months from 44.57 weeks as posted
CV Death 11.14 vs 9.66 Darbepoetin Alfa months
absolute value · months
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 48.29 weeks as posted
show 3 more results
11.14 vs 12.51 Darbepoetin Alfa months*
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 48.29 weeks as posted
5.08 vs 13.42 Darbepoetin Alfa months*
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 22 weeks as posted
10.65 vs 10.99 Darbepoetin Alfa months*
NCT02892149 · Phase 3 · converted to months from 46.14 weeks as posted
Overall Survival 10.75 vs 11.03 Darbepoetin Alfa months
time to event · months
NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 46.57 weeks as posted
show 3 more results
13.32 vs 14.34 Darbepoetin Alfa months*
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 57.71 weeks as posted
7.32 vs 10.47 Darbepoetin Alfa months*
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to months from 31.71 weeks as posted
11.72 vs 11.64 Darbepoetin Alfa months*
NCT02892149 · Phase 3 · converted to months from 50.79 weeks as posted
Hemoglobin Change g/dL 0.08 vs -1.48 placebo g @ 6wk300 mg
absolute change · g
NCT03054350 · Phase 2 · registry result, not featured evidence
show 16 more results
1.13 vs -0.47 placebo g @ 6wk300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0.14 vs 0.36 Mircera® g900 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
-0.22 vs 0.16 Mircera® g900 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
-0.07 vs 0.36 Mircera® g600 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
-0.11 vs 0.16 Mircera® g600 mg TIW
NCT04707768 · Phase 3 · registry result, not featured evidence
0.41 vs -1.48 placebo g @ 6wk600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
1.62 vs -0.47 placebo g @ 6wk600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
1.43 vs -0.03 placebo g @ 6wk630 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
1.25 vs -0.03 placebo g @ 6wk500 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0.73 vs -0.03 placebo g @ 6wk370 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
0.77 vs -0.03 placebo g @ 6wk240 mg
NCT01381094 · Phase 2 · registry result, not featured evidence
-0.28 vs -1.48 placebo g @ 6wk150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
0.43 vs -0.47 placebo g @ 6wk150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence
0.41 vs 0.42 Darbepoetin Alfa g @ 36wk
NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.26 vs 1.58 Darbepoetin Alfa g @ 36wk
NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
0.19 vs 0.36 Darbepoetin Alfa g
NCT02892149 · Phase 3
Hemoglobin Change g/dL -0.371 vs 0.16 Epoetin Alfa g @ 12wk300 mg
absolute change · g
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
show 5 more results
-0.911 vs 0.16 Epoetin Alfa g @ 12wk300 mg
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
-0.418 vs 0.16 Epoetin Alfa g @ 12wk600 mg
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
-0.671 vs 0.16 Epoetin Alfa g @ 12wk600 mg
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
0.072 vs 0.16 Epoetin Alfa g @ 12wk450 mg
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
-0.284 vs 0.16 Epoetin Alfa g @ 12wk450 mg
Change from Baseline at PEP
NCT03799627 · Phase 2 · registry result, not featured evidence
Hemoglobin in Target Range 40% (n=30) vs 65.2% (n=23) Epoetin Alfa @ 12wk300 mg
event count · % of participants
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 12 Participants as posted
show 11 more results
8.3% (n=12) vs 65.2% (n=23) Epoetin Alfa @ 12wk*300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
23.1% (n=26) vs 39.1% (n=23) Epoetin Alfa @ 20wk*300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
28.6% (n=7) vs 39.1% (n=23) Epoetin Alfa @ 20wk*300 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
28.6% (n=14) vs 65.2% (n=23) Epoetin Alfa @ 12wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
0% (n=4) vs 65.2% (n=23) Epoetin Alfa @ 12wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
20% (n=10) vs 39.1% (n=23) Epoetin Alfa @ 20wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
33.3% (n=3) vs 39.1% (n=23) Epoetin Alfa @ 20wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
43.3% (n=30) vs 65.2% (n=23) Epoetin Alfa @ 12wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 13 Participants as posted
22.2% (n=18) vs 65.2% (n=23) Epoetin Alfa @ 12wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
29.2% (n=24) vs 39.1% (n=23) Epoetin Alfa @ 20wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
21.4% (n=14) vs 39.1% (n=23) Epoetin Alfa @ 20wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Hemoglobin in Target Range 0% (n=1) @ 20wk300 mg
event count · % of participants
No placebo or comparator arm
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 3 more results
28.6% (n=7) @ 20wk*600 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
60% (n=5) @ 20wk*750 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
50% (n=4) @ 20wk*450 mg
NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
Time to Hgb Target 2.6 months @ 16wk300 mg
time to event · months
No placebo or comparator arm
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 79.2 days as posted
show 7 more results
1.87 months @ 16wk*300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 57 days as posted
1.28 months*300 mg
NCT03054337 · Phase 2 · registry result, not featured evidence · converted to months from 39 days as posted
1.79 months @ 16wk*600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 54.6 days as posted
2.79 months @ 16wk*600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 85 days as posted
0.84 months*600 mg
NCT03054337 · Phase 2 · registry result, not featured evidence · converted to months from 25.6 days as posted
2.28 months @ 16wk*150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence · converted to months from 69.3 days as posted
1.87 months*150 mg
NCT03054337 · Phase 2 · registry result, not featured evidence · converted to months from 56.8 days as posted
Hemoglobin Level g/dL 9.062 vs 7.817 placebo g/dL @ 6wk300 mg
absolute value · g/dL
NCT03054350 · Phase 2 · registry result, not featured evidence
show 10 more results
9.969 vs 7.817 placebo g/dL @ 6wk600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
9.064 vs 7.817 placebo g/dL @ 6wk150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
10.02 vs 9.74 placebo g/dL @ 2wk
NCT01906489 · Phase 2 · registry result, not featured evidence
10.35 vs 9.7 placebo g/dL @ 4wk
NCT01906489 · Phase 2 · registry result, not featured evidence
10.61 vs 9.6 placebo g/dL @ 6wk
NCT01906489 · Phase 2 · registry result, not featured evidence
10.66 vs 9.6 placebo g/dL @ 8wk
NCT01906489 · Phase 2 · registry result, not featured evidence
10.87 vs 9.82 placebo g/dL @ 12wk
NCT01906489 · Phase 2 · registry result, not featured evidence
10.79 vs 9.83 placebo g/dL @ 16wk
NCT01906489 · Phase 2 · registry result, not featured evidence
10.74 vs 9.93 placebo g/dL @ 19wk
NCT01906489 · Phase 2 · registry result, not featured evidence
10.88 vs 9.93 placebo g/dL @ 20wk
NCT01906489 · Phase 2 · registry result, not featured evidence
Hemoglobin Level g/dL 11.285 g/dL @ 16wk300 mg
absolute value · g/dL
Maintenance
No placebo or comparator arm
NCT03054350 · Phase 2 · registry result, not featured evidence
show 5 more results
13.2 g/dL @ 16wk300 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
11.1 g/dL @ 16wk600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
12.1 g/dL @ 16wk600 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
10.46 g/dL @ 16wk150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence
8.6 g/dL @ 16wk150 mg
NCT03054350 · Phase 2 · registry result, not featured evidence

+ 26 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Desidustat's landscape · Vadadustat's landscape